CAS 1010412-80-2

Formule : C32H37NO6

InChI : InChI=1S/C32H37NO6/c1-32(2,3)24-12-10-23(11-13-24)29-27-8-6-7-9-28(27)33(30(29)31(34)35)21-22-18-25(38-16-14-36-4)20-26(19-22)39-17-15-37-5/h6-13,18-20H,14-17,21H2,1-5H3,(H,34,35)

Code InChI : OIDYMQICWGYEDR-UHFFFAOYSA-N

SMILES : CC(C)(C)C1=CC=C(C=C1)C2=C(N(C3=CC=CC=C32)CC4=CC(=CC(=C4)OCCOC)OCCOC)C(=O)O

GSK376501A

CAS : 1010412-80-2

GSK376501A

Formule : C₃₂H₃₇NO₆

Degré de pureté : 99.5%

Masse moléculaire : 531.64

Ref: 54-BUP20523

GSK376501A

CAS : 1010412-80-2

Formule : C₃₂H₃₇NO₆

Degré de pureté : 97%

Masse moléculaire : 531.6393

Ref: IN-DA01EOP3

GSK376501A

CAS : 1010412-80-2

GSK376501A is a selective and effective modulator of peroxisome proliferator-activated receptor γ (PPARγ) for the study of type 2 diabetes.

Formule : C₃₂H₃₇NO₆

Degré de pureté : 97.71% - >99.99%

Couleur et forme : White Solid

Masse moléculaire : 531.64

Ref: TM-T15440

GSK376501A

CAS : 1010412-80-2

GSK376501A is an ethylene oxide-based compound that is used in the synthesis of aryl halides. GSK376501A has been used as an intermediate for the synthesis of a number of potential therapeutic agents, such as anti-diabetic drugs. This compound has also been shown to be a nucleophilic agent and can be used in process development. GSK376501A is also effective at inhibiting glucose release from pancreatic cells in vitro, suggesting it may have potential therapeutic use in diabetes treatment.

Formule : C₃₂H₃₇NO₆

Degré de pureté : Min. 95%

Masse moléculaire : 531.6 g/mol

Ref: 3D-KQB41280